China Medical System secured exclusive rights to commercialize Atom Therapeutics' ABP-671 in Mainland China, Hong Kong, and Macao for gout and hyperuricemia treatment.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.